Navmi
(Ivonescimab)Phase 3Monoclonal antibody
Ivonescimab is used to treat certain types of cancer by helping the immune system recognize and attack cancer cells that would otherwise hide from it.[1] Navmi is currently being investigated across 45 indications[3], with its most advanced program in Phase 3.[1]
Navmi is one of 751 bispecific antibody programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.
45
Indications
65
Total Trials
63
Active Trials
750
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 45 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Navmi
SSummit Therapeutics
Phase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer7 trials
Ivonescimab3 trials
Breast Cancer2 trials
Metastatic Colorectal Cancer2 trials
45 more indications
Pancreatic Cancer2 trials
Locally-advanced Rectal Cancer2 trials
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06760520·40 enrolled
First-line Treatment2 trials
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
Not yet recruiting·—·Phase 1/2·NCT07339839·42 enrolled
Adenocarcinoma2 trials
Advanced Malignant Tumors1 trial
Triple-Negative Breast Cancer1 trial
Squamous Cell Carcinoma1 trial
Salivary Gland Cancer1 trial
Locally Advanced Colon Cancer1 trial
Brain Metastases1 trial
A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC
Not yet recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT07234877·158 enrolled
Advanced NSCLC1 trial
Esophageal Adenocarcinoma1 trial
Nasopharyngeal Carcinoma1 trial
Cutaneous Squamous Cell Carcinoma1 trial
mRNA Vaccine1 trial
Multiple Advanced Tumors After PD-1 Therapy Failure1 trial
Adrenocortical Carcinoma1 trial
SCLC, Recurrent1 trial
Squamous Non-Small Cell Lung Cancer SqNSCLC1 trial
Neoplasms, Lung1 trial
Colorectal Cancer1 trial
Advanced Microsatellite Stable Colorectal Carcinoma1 trial
Gastric Carcinoma1 trial
Biliary Tract Cancer1 trial
Leiomyosarcoma1 trial
Small Cell Lung Cancer1 trial
Cutaneous Angiosarcoma1 trial
Pleural Mesotheliomas1 trial
Rectal Cancer1 trial
Clear Cell Renal Cell Carcinoma1 trial
TNBC1 trial
Solid Tumor1 trial
Lung Cancer (NSCLC)1 trial
Thymus Carcinoma1 trial
Advanced Head and Neck Squamous Cell Carcinoma1 trial
NSCLC (Advanced Non-small Cell Lung Cancer)1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ivonescimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- PD-1/VEGF Bispecific[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- SSummit Therapeutics